Durham-based Bioventus names veteran life science exec as CEO
The Board of Directors of Durham-based Bioventus Inc. appointed Robert Claypoole as president and chief executive officer and a member of its board, effective January 10, 2024.
Read More
bioventus
Durham biotech firm Bioventus ousts CEO, hires predecessor on interim basis
Bioventus announced the departure of its chief executive officer – Kenneth Reali – early Wednesday but an SEC filing says the company’s board “determined that he would transition from his role” on Monday.
Read More
Bioventus to pay millions in deal that could lead to cancellation of $315M purchase
In the latest twist of an acquisition saga dating back some three years Durham-based life science firm Bioventus is to pay millions of dollars to shareholders of a company it announced plans to acquire for $350 million.
Read More
Earnings reports: Bioventus, Humacyte, Guerrilla RF, Novan, Liquidia & more
It’s been a busy week for North Carolina public companies in tech and life science reporting financial results. Here’s a roundup.
Read More
After amending the deal, Bioventus completes purchase of Israeli company CartiHeal
Bioventus has completed the acquisition of CartiHeal, an Israeli firm, following a decision to amend the deal earlier this year.
Read More
Earnings rreports: Avaya, Duke Energy, Precision Bio, Bioventus
Earnings season continues with more North Carolina companies reporting quarterly financials. Here are the latest.
Read More
A week after announcing, Durham’s Bioventus says it will cancel $415M debt funding round
Bioventus has withdrawn a $415 million offering of senior notes, one week after announcing that the company would raise funds to close a recent acquisition.
Read More
Triangle life science firm Bioventus seeks to raise $415M in debt
Durham-based Bioventus will open an additional $415 million in debt fundraising. The company also reported a surge in revenues. Here are the details.
Read More
Bioventus completes acquisition of Israeli firm CartiHeal in deal worth up to $450M
Bioventus has chosen to exercise its option to acquire an Israeli firm, CartiHeal, following the premarket approval of its technology by the U.S. FDA.
Read More
